Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 175 of 942 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/30/19
End: 03/06/23
Due: 03/06/24
Phase: N/A
Priority: Normal
Start: 05/01/25
End: 05/31/30
Due: 05/31/31
Phase: N/A
Priority: Normal
Start: 06/06/16
End: 12/01/20
Due: 12/01/21
Phase: N/A
Priority: Normal
Start: 02/18/15
End: 03/15/28
Due: 03/15/29
Phase: N/A
Priority: Normal
Start: 05/10/19
End: 05/31/29
Due: 05/31/30
Phase: N/A
Priority: Normal
Start: 03/27/14
End: 11/04/18
Due: 11/04/19
Phase: N/A
Priority: Normal
Start: 03/01/19
End: 03/01/20
Due: 03/01/21
Phase: N/A
Priority: Normal
Start: 11/28/23
End: 11/28/28
Due: 11/28/29
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 06/30/20
Due: 06/30/21
Phase: N/A
Priority: Normal
Start: 02/01/06
End: 02/01/06
Due: 02/01/07
Phase: N/A
Priority: Normal
Start: 05/10/16
End: 01/31/17
Due: 01/31/18
Phase: N/A
Priority: Normal
Start: 05/05/22
End: 04/30/25
Due: 04/30/26
Phase: N/A
Priority: Normal
Start: 11/14/24
End: 07/01/28
Due: 07/01/29
A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients
Phase: N/A
Priority: Normal
Start: 04/30/14
End: 04/30/16
Due: 04/30/17
Phase: N/A
Priority: Normal
Start: 12/11/17
End: 06/15/21
Due: 06/15/22
Phase: N/A
Priority: Normal
Start: 07/01/25
End: 03/31/26
Due: 03/31/27
Phase: N/A
Priority: Normal
Start: 05/31/10
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 01/31/17
End: 12/31/21
Due: 12/31/22
Phase: N/A
Priority: Normal
Start: 03/01/22
End: 03/31/26
Due: 03/31/27
Phase: N/A
Priority: Normal
Start: 04/24/18
End: 04/30/29
Due: 04/30/30
Phase: N/A
Priority: Normal
Start: 12/20/23
End: 12/31/27
Due: 12/31/28
Phase: N/A
Priority: Normal
Start: 06/30/10
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 10/22/19
End: 06/30/23
Due: 06/30/24
Phase: N/A
Priority: Normal
Start: 04/30/07
End: 09/30/12
Due: 09/30/13
Phase: N/A
Priority: Normal
Start: 05/15/15
End: 09/20/17
Due: 09/20/18